Business Context and Reporting Period
Company: Chemed Corporation
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and nine months ended September 30, 1994
Business Overview: Chemed operates through four primary segments: National Sanitary Supply, Roto-Rooter, Veratex, and Patient Care (acquired January 1, 1994). The company provides sanitary supplies, plumbing and drain cleaning services, medical equipment, and home health care services.
Key Financial Metrics
| Metric (in thousands) | Q3 1994 | Q3 1993 | 9 Months 1994 | 9 Months 1993 |
|---|---|---|---|---|
| Total Sales & Service Revenues | $166,089 | $139,824 | $479,542 | $387,584 |
| Income from Operations | $6,348 | $7,086 | $18,484 | $16,278 |
| Net Income | $5,094 | $4,158 | $18,788 | $15,438 |
| Diluted EPS (Net Income) | $0.52 | $0.43 | $1.91 | $1.58 |
| Operating Cash Flow (9 Months) | $14,447 (1994) vs $15,348 (1993) | |||
| Total Assets | $481,771 (Sep 30, 1994) | |||
| Total Liabilities | $330,283 (Sep 30, 1994) | |||
| Long-Term Debt | $108,072 (Sep 30, 1994) | |||
| Cash & Equivalents | $15,699 (Sep 30, 1994) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 19% in Q3 and 24% for the nine-month period compared to 1993. This growth was driven primarily by the acquisition of Patient Care Inc. and the Roto-Rooter segment (up 34% for nine months).
- Operating Profit: Operating income declined 10% in Q3 ($6.3M vs $7.1M) due to $1.7M in nonrecurring expenses at Veratex and headquarters. However, for the nine-month period, operating income increased 14% to $18.5M.
- Net Income: Net income rose 23% in Q3 and 22% for the nine-month period. This increase was significantly aided by gains on the sale of investments ($10.2M pretax gain for nine months) and favorable adjustments to discontinued operations ($3.8M).
- Acquisitions: The acquisition of Patient Care Inc. (Jan 1, 1994) added $50.4M in revenue and $1.8M in operating profit for the nine-month period. Goodwill increased by $3.3M due to a contingent payment accrual for the Encore Services acquisition.
- Investment Gains: Realized gains on the sale of Omnicare, Inc. stock and other investments were a major contributor to "Other Income," totaling $14.9M for the nine months ended Sept 30, 1994.
Guidance, Outlook, and Risks
- Management Commentary: Management expects the staff downsizing at Veratex to generate approximately $770,000 in annual after-tax cost savings. Consolidation of purchasing functions for the Encore acquisition is expected to lower material costs.
- Liquidity: The company maintains approximately $31.8M in unused lines of credit. A new $10M term loan was secured in March 1994 to finance the Patient Care acquisition. Management believes current liquidity and operating cash flows are sufficient for anticipated needs.
- Risks and Contingencies:
- Regulatory Approval: Final approval for the transfer of ownership of one Patient Care region is expected in November 1994.
- Contingent Payments: Up to $10.4M in additional cash payments may be due for Patient Care based on earnings through 1995. A $3.8M contingent payment for Encore is due in 1996.
- Discontinued Operations: Favorable accrual adjustments of $3.8M related to discontinued operations (sold in 1991) were recorded; management notes that additional adjustments may be necessary due to the long-term nature of these accruals.
- Accounting Changes: Adoption of SFAS 115 resulted in investments being recorded at fair value, creating $6.9M in unrealized appreciation included in equity.
Investor Verification Checklist
- Nonrecurring Items: Verify the sustainability of earnings by excluding the $1.7M Veratex restructuring charge and the $10.2M investment gains.
- Acquisition Integration: Monitor the performance of Patient Care Inc. and the realization of cost savings from the Encore integration.
- Debt Obligations: Review the terms of the new $10M term loan and the potential for additional contingent payments on acquisitions.
- Discontinued Operations: Assess the likelihood of future adjustments to the $3.8M gain recorded from discontinued operations.
- Omnicare Exposure: Note the decline in equity earnings from Omnicare due to one-time expenses at the affiliate and the impact of future sales of this investment.